Heredia Vladi V, Carlson Thomas J, Garcia Erin, Sun Shaoxian
Department of Biochemical Pharmacology, La Jolla Laboratories, Pfizer Global Research and Development, San Diego, California 92121, USA.
J Biol Chem. 2006 Dec 29;281(52):40201-7. doi: 10.1074/jbc.M607987200. Epub 2006 Nov 2.
Glucokinase (GK) has several known polymorphic activating mutations that increase the enzyme activity by enhancing glucose binding affinity and/or by alleviating the inhibition of glucokinase regulatory protein (GKRP), a key regulator of GK activity in the liver. Kinetic studies were undertaken to better understand the effect of these mutations on the enzyme mechanism of GK activation and GKRP regulation and to relate the enzyme properties to the associated clinical phenotype of hypoglycemia. Similar to wild type GK, the transient kinetics of glucose binding for activating mutations follows a general two-step mechanism, the formation of an enzyme-glucose complex followed by an enzyme conformational change. However, the kinetics for each step differed from wild type GK and could be grouped into specific types of kinetic changes. Mutations T65I, Y214C, and A456V accelerate glucose binding to the apoenzyme form, whereas W99R, Y214C, and V455M facilitate enzyme isomerization to the active form. Mutations that significantly enhance the glucose binding to the apoenzyme also disrupt the protein-protein interaction with GKRP to a large extent, suggesting these mutations may adopt a more compact conformation in the apoenzyme favorable for glucose binding. Y214C is the most active mutation (11-fold increase in k(cat)/K(0.5)(h)) and exhibits the most severe clinical effects of hypoglycemia. In contrast, moderate activating mutation A456V nearly abolishes the GKRP inhibition (76-fold increase in K(i)) but causes only mild hypoglycemia. This suggests that the alteration in GK enzyme activity may have a more profound biological impact than the alleviation of GKRP inhibition.
葡萄糖激酶(GK)有几种已知的多态性激活突变,这些突变通过增强葡萄糖结合亲和力和/或减轻葡萄糖激酶调节蛋白(GKRP)对其的抑制作用来提高酶活性,GKRP是肝脏中GK活性的关键调节因子。进行动力学研究以更好地理解这些突变对GK激活的酶机制和GKRP调节的影响,并将酶特性与相关的低血糖临床表型联系起来。与野生型GK相似,激活突变的葡萄糖结合瞬态动力学遵循一般的两步机制,即先形成酶-葡萄糖复合物,然后发生酶构象变化。然而,每一步的动力学与野生型GK不同,可分为特定类型的动力学变化。突变T65I、Y214C和A456V加速葡萄糖与脱辅基酶形式的结合,而W99R、Y214C和V455M促进酶异构化为活性形式。显著增强葡萄糖与脱辅基酶结合的突变也在很大程度上破坏了与GKRP的蛋白质-蛋白质相互作用,这表明这些突变可能在脱辅基酶中采用更紧凑的构象,有利于葡萄糖结合。Y214C是活性最高的突变(k(cat)/K(0.5)(h)增加11倍),并表现出最严重的低血糖临床效应。相比之下,中度激活突变A456V几乎消除了GKRP抑制作用(K(i)增加76倍),但仅导致轻度低血糖。这表明GK酶活性的改变可能比GKRP抑制作用的减轻具有更深远的生物学影响。